Effectiveness and serotype coverage: Key criteria for pneumococcal vaccines for adults

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 255-258

  Plotkin, Stanley ^a   Grabenstein, John D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOASSAY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPE; STREPTOCOCCUS PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 84864149080     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis354     Document Type: Article

References (34)

1. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945; 81:445-65.
2. Klugman KP, Hayden Smith SW, Koornhof HJ. Evidence that prevention of carriage by pneumococcal capsular vaccines may be the mechanism of protection from pneumococcal pneumonia. S Afr J Epidemiol Infect 2011; 26:1-4.
3. Austrian R. Pneumococcal vaccine and pneumococcal pneumonia. Ann Intern Med 1988; 108:762 (letter).
4. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008; doi:10.1002/14651858.CD000422.pub2. http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD000422/frame.html. Accessed 16 April 2012. (Pubitemid 351807720)
5. Fedson D, Nicolas-Spony L, Klemets P, et al. 23-valent pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Review Vaccines 2011; 10:1143-67.
6. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004 (1-7).
7. Advisory committee on immunization practices. Pneumococcal polysaccharide vaccine. MMWR 1978; 27:25-6, 31.
8. Hilleman MR, Carlson AJ Jr, McLean AA, Vella PP, Weibel RE, Woodhour AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981; 3(suppl):S31-42.
9. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148:1136-59. (Pubitemid 14206325)
10. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine usage-United States. MMWR 1984; 33:273-6, 281.
11. Avery OT, Goebel WF. Chemical-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50:533-42.
12. Avery OT, Goebel WF. Chemical-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J Exp Med 1931; 54:437-47.
13. French N, Gordon SB, Mwalukomo T, et al. A trial of A 7-valent pneumococcal conjugate vaccine in hiv-infected adults. N Engl J Med 2010; 362:812-22.
14. Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83.
15. Study evaluating a 13-valent pneumococcal conjugate vaccine (13vPnC) in adults (CAPITA). Available at: http://www.clinicaltrials. gov/ct2/show/ NCT00744263. Accessed 14 December 2011.
16. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22:927-46. (Pubitemid 38228353)
17. Pilishvili T, Lexau C, Farley MM, et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
18. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205-12.
19. Lehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010; 50:1477-86.
20. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in england and wales: an observational cohort study. Lancet Infect Dis 2011; 11:760-8.
21. Grall N, Hurmic O, Al Nakib M, et al. Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 2011; 30:1511-9.
22. Imöhl M, Reinert RR, van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int J Microbiol 2010; 300:237-47.
23. Horácio AN, Diamantino-Miranda J, Aguiar SI, Ramirez M, Melo-Cristino J; the Portuguese Group for the Study of Streptococcal Infections. Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections. Vaccine 2012; 30:218-24.
24. Skoczyska A, Sadowy E, Bojarska K, et al. Participants of laboratorybased surveillance of community acquired invasive bacterial infections (BINet). The current status of invasive pneumococcal disease in Poland. Vaccine 2011; 29:2199-205.
25. Hsieh YC, Lin PY, Chiu CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009; 27:5513-8.
26. Jefferies JM, Clarke SC, Webb JS, Kraaijeveld AR. Risk of Red Queen dynamics in pneumococcal vaccine strategy. Trends Microbiol 2011; 19:377-81.
27. Grabenstein JD, Manoff SB. Pneumococcal vaccines in adults: assessing the evolving evidence. Vaccine 2011; 29:6149-54.
28. Musher DM, Manoff SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516-24.
29. Manoff SB, Liss C, Caulfield MJ, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged >65 years. J Infect Dis 2010; 201:525-33.
30. Musher DM, Manoff SB, McFetridge RD, et al. Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of 2nd and 3rd doses in older adults. Hum Vaccine 2011; 7:919-28.
31. Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011; 29:2287-95.
32. Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010; 201:659-61.
33. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine. MMWR 1997; 46(RR-8):1-24. ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/ rr4608.pdf. Accessed 16 April 2012.
34. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281: 243-8. (Pubitemid 29058113)